| abstract |
The cancer gene therapeutic drug of the present invention comprises an immunotherapeutic virus administered to induce a CTL response of a living body, and a carrier cell for infecting an oncolytic virus prior to administration to act the same virus on tumor cells of the living body. It is a combination. As a carrier cell, A549 cell can be used, for example. As the virus for immunological treatment, for example, a non-proliferative adenovirus inactivated by ultraviolet irradiation, and an oncolytic virus, for example, a proliferative adenovirus having a tumor specific promoter can be used. . |